Cogent Biosciences (COGT) Non-Current Deffered Revenue (2017 - 2018)
Cogent Biosciences (COGT) posted quarterly Non-Current Deffered Revenue of $748000.0 for Q4 2018, down 91.42% year-over-year from $8.7 million in Q4 2017, and down 14.12% quarter-over-quarter from $871000.0 in Q3 2018.
Cogent Biosciences (COGT) Non-Current Deffered Revenue (2017 - 2018) Analysis & Trends
Cogent Biosciences (COGT) has reported Non-Current Deffered Revenue for 2 consecutive years, with $748000.0 the latest figure, recorded in Q4 2018.
- In Q4 2018, Non-Current Deffered Revenue fell 91.42% year-over-year to $748000.0; the TTM figure through Dec 2018 stood at $748000.0 (down 91.42% YoY), while the FY2018 annual figure was $748000.0, down 91.42% from the prior year.
- Non-Current Deffered Revenue eased to $748000.0 in Q4 2018 per COGT's latest filing, from $871000.0 in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $8.7 million in Q4 2017 and bottomed at $346000.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 220.40 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Cogent Biosciences | 6.58 Bn | 6.58 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 748,000.00 |
| Sep 30, 2018 | 871,000.00 |
| Jun 30, 2018 | 346,000.00 |
| Mar 31, 2018 | 902,000.00 |
| Dec 31, 2017 | 8.71 Mn |